Evidence map›Paper›PMID 40277813›Full record

ArticleDiseases (Basel, Switzerland)2025

Study of Adult and Pediatric Spanish Patients with Cryptogenic Splenomegaly and Splenectomy.

Marta Morado Arias, Jesús Villarrubia Espinosa, Isidro Vitoria Miñana, Enrique Calderón Sandubete, Víctor Quintero, Miguel Ángel Torralba-Cabeza

Abstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marta Morado AriasDepartment of Hematology and Hemotherapy, Hospital Universitario La Paz, 28046 Madrid, Spain.
Jesús Villarrubia EspinosaDepartment of Hematology and Hemotherapy, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Isidro Vitoria MiñanaNutrition and Metabolic Disease Unit, Hospital Universitario La Fe, 46026 Valencia, Spain.
Enrique Calderón SandubeteDepartment of Internal Medicine and Biomedicine Institute, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.ORCID 0000-0002-3166-5086
Víctor QuinteroDepartment of Pediatric Hematology-Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.ORCID 0000-0003-4590-3062
Miguel Ángel Torralba-CabezaDepartment of Internal Medicine, Hospital Universitario Lozano Blesa, 50009 Zaragoza, Spain.ORCID 0000-0002-0451-3597

Funding

Sanofi (Spain) 2019
6 · The paper itself

Abstract

introductionThe differential diagnosis of splenomegaly is a complex process that encompasses a wide variety of diseases. Moreover, it is not always standardized and lacks a definitive consensus on which tests should be performed and in what order. Gaucher disease (GD) and acid sphingomyelinase deficiency (ASMD) are lysosomal diseases (LD) that present with splenomegaly, the diagnosis of which requires a high index of suspicion and specific biochemical and genetic techniques. The aim of the project for the education and diagnosis of Gaucher disease and acid sphingomyelinase deficiency (PREDIGA) was to conduct educational training alongside an observational, multicenter, ambispective, cross-sectional, single-cohort study among patients having an enlarged spleen or undergone splenectomy to further assess these subjects to exclude two lysosomal diseases, namely GD and ASMD.

methodsUsing dried blood spot (DBS) testing, we identified patients with abnormally low values of the enzymes glucocerebrosidase and acid sphingomyelinase, who then underwent sequencing of the GBA1 and SPMD1 genes, respectively. The study involved 34 hospitals and 52 medical specialists.

resultsWe identified 220 patients (208 adults and 12 children under 18 years) with cryptogenic splenomegaly or who had undergone splenectomy (12 patients) without having reached a diagnosis. The median age was 11 years (interquartile range [IQR] 3-16) in the pediatric population and 51 years (IQR 38-65) in the adult population. Lower-than-normal enzyme values were detected in 19 DBSs, confirming eight positive cases, which corresponded to six patients with GD and two with ASMD. The rest of the DBSs with low enzyme activity were not genetically confirmed (58%). We determined that lysosomal diseases accounted for 3.6% of cryptogenic splenomegaly/splenectomy cases in our setting: 2.7% were GD and 0.9% ASMD, in a ratio of 1 ASMD patient to every 3 GD patients. Lyso-GL1 values in patients with GD were elevated in all but one individual, corresponding to a child diagnosed at 4 months old. The variants detected in the GBA1 gene were consistent with the most frequent variants found in Spain. DISCUSSION/

conclusionThe development and implementation of this protocol for the education and diagnosis of cryptogenic splenomegaly/splenectomy, even in asymptomatic patients, constitutes a comprehensive, simple, rapid, and effective screening method for the diagnosis of GD and ASMD.

Indexed as

ASMDDBSGauchersplenectomysplenomegaly

Identifiers

PMID40277813
PMCPMC12025833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.